시장보고서
상품코드
1709462

세계의 신경 보호 시장 : 제품 유형별, 적응증별, 작용기전별, 최종사용자별, 국가별, 지역별 - 산업 분석, 시장 규모, 점유율, 예측(2025-2032년)

Neuroprotection Market, By Product Type, By Disease Indication, By Mechanism of Action, By End User, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

발행일: | 리서치사: AnalystView Market Insights | 페이지 정보: 영문 309 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

신경 보호 시장 규모는 2024년 340억 9,243만 달러로 평가되었고, 2025-2032년 연평균 7.42%의 성장률을 나타낼 것으로 예상됩니다.

이 시장의 성장을 주도하는 것은 신경 질환의 유병률 증가, 의학 연구의 발전, 효과적인 치료에 대한 수요 증가입니다. 또한, 세계 인구의 고령화는 신경 퇴행성 질환이 더욱 보편화됨에 따라 시장을 더욱 활성화시킬 것입니다. 각 기업은 혁신적인 솔루션에 많은 투자를 하고 있으며, 이는 신경 보호에 대한 치료 옵션의 확대로 이어지고 있습니다.

신경 보호 시장 역학

신경퇴행성 질환의 조기 진단을 위한 바이오마커 탐색의 발전.

바이오마커 발굴의 발전은 신경퇴행성 질환의 조기 진단에 중요한 역할을 하며, 신경 보호 시장을 크게 견인하고 있습니다. 바이오마커는 신경장애를 조기에 발견하여 보다 빠르고 효과적인 개입을 가능하게 합니다. 바이오마커는 특정 질병 하위 유형을 식별하고 진행을 예측할 수 있기 때문에 이러한 발견은 맞춤 치료 접근법을 촉진합니다. 진단 정확도가 향상되면 적시에 치료하고 더 나은 관리를 보장함으로써 의료 비용을 절감할 수 있습니다.

학계와 연구기관은 획기적인 발전을 촉진하는 공동연구를 통해 이 분야를 선도하고 있습니다. 예를 들어, 미국 국립노화연구소(NIA)는 알츠하이머병 바이오마커 연구에 적극적으로 자금을 지원하여 몇 가지 유망한 진단 마커를 개발했으며, NIA에 따르면 연간 3억 달러 이상이 알츠하이머병 연구에 할당되어 있으며, 그 중 상당 부분이 바이오마커 개발에 집중되어 있다고 합니다. 바이오 마커 개발에 초점을 맞추었습니다. 이러한 개발은 진단 정확도를 높일 뿐만 아니라 신경 퇴행성 치료의 정밀의료라는 광범위한 추세를 뒷받침하고 있습니다.

신경 보호 시장 : 주요 고찰

당사의 리서치 애널리스트들이 공유한 분석에 따르면, 세계 시장은 예측 기간(2025-2032) 동안 약 7.42%의 연평균 복합 성장률(CAGR)로 매년 성장할 것으로 추정됩니다.

제품 유형별로 시장 세분화는 2024년에 가장 큰 시장 점유율을 보일 것으로 예상됩니다.

적응증별로는 알츠하이머병이 2024년 주요 적응증으로 나타났습니다.

작용기전별로는 2024년 항산화제가 주요 작용기전이었습니다.

최종 사용자별로는 병원이 2024년 주요 최종 사용자로 나타났습니다.

지역별로는 북미가 2024년 수익을 창출할 주요 시장입니다.

신경 보호 시장 : 세분화 분석

세계 신경 보호 시장은 제품 유형, 적응증, 작용기전, 최종 사용자, 지역별로 분류됩니다.

시장은 제품 유형에 따라 약물과 장비의 두 가지 범주로 나뉩니다. 신경 보호 시장에서는 약물이 가장 중요한 부문입니다. 알츠하이머병, 파킨슨병, 다발성 경화증과 같은 신경 질환 및 증상의 치료에 직접적인 역할을 하기 때문에 시장을 독점하고 있습니다. 신경보호제를 포함한 약물은 질병의 진행을 늦추고, 뉴런을 손상으로부터 보호하며, 환자의 삶의 질을 개선하도록 설계되어 있습니다. 이 분야는 현재 진행 중인 연구, 임상시험 및 규제 당국의 승인을 통해 새로운 약수처리에 대한 수요를 주도하고 있습니다. 신경과학의 발전이 보다 효과적인 치료법으로 이어지면서 신경보호제 시장은 지속적으로 성장할 것으로 예상됩니다.

시장은 적응증별로 파킨슨병, 알츠하이머병, 뇌졸중, 다발성 경화증, 근위축성 측색경화증(ALS), 외상성 뇌손상(TBI), 기타 등 6가지 카테고리로 분류됩니다. 신경보호제 시장에서 알츠하이머병은 가장 중요한 질환 적응증입니다. 전 세계적으로 높은 유병률과 고령화 인구 증가로 인해 가장 큰 점유율을 차지하고 있습니다. 알츠하이머병은 광범위한 신경 변성을 유발하여 진행을 늦추기 위한 신경 보호 요법에 대한 큰 수요를 창출하고 있습니다. 의약품 개발의 지속적인 발전과 효과적인 치료법 발견에 대한 관심 증가는 이 부문을 발전시키고 있습니다. 알츠하이머병은 혁신적인 치료법에 대한 필요성이 증가함에 따라 연구자들과 제약회사들의 관심의 초점이 되고 있습니다.

신경 보호 시장 : 지역별 분석

북미 신경보호제 시장은 인구 고령화, 알츠하이머병, 파킨슨병, 다발성 경화증과 같은 신경퇴행성 질환의 유병률 증가, 생명공학 및 의약품의 발전 등을 배경으로 큰 성장세를 보이고 있습니다. 미국이 가장 큰 점유율을 차지하고 있는 것은 강력한 의료 인프라, 풍부한 연구 자금, 치료 솔루션에 대한 높은 수요에 기인합니다. 캐나다도 신경 보호 연구개발에 대한 투자 확대로 시장에 기여하고 있습니다. 또한, 초기 단계의 개입과 예방 치료, 새로운 약물 요법에 대한 관심도 증가하고 있습니다. 정부의 이니셔티브와 학계 및 민간 기업과의 협력으로 신경보호제 기술 혁신이 진행되고 있습니다. 그러나 높은 약품 개발 비용과 규제적 장애물이라는 과제도 남아있습니다. 그럼에도 불구하고 시장 전망은 여전히 낙관적이며, 업계 주요 기업들은 미충족 의료 수요를 충족시키기 위한 새로운 치료 전략을 모색하고 있습니다.

미국은 북미 신경보호제 시장에서 지배적인 국가이며, 그 주된 이유는 선진적인 의료 시스템, 높은 연구개발 수준, 의료 기술 혁신에 대한 막대한 정부 자금 지원입니다. 미국에는 신경퇴행성 질환에 특화된 주요 생명공학 기업 및 제약기업이 다수 존재하여 신경보호요법의 빠른 개발 및 상용화에 기여하고 있습니다. 또한, 미국은 인구가 많고 고령화가 진행되어 치료에 대한 수요가 증가하고 있으며, 이는 시장 성장의 주요 요인으로 작용하고 있습니다.

신경 보호 시장 : 경쟁 구도

신경보호제 시장 경쟁 구도는 제약사, 생명공학 기업, 연구기관 간의 치열한 경쟁으로 특징지어지며, 이들 모두 신경질환에 대한 효과적인 치료법을 개발하기 위해 경쟁하고 있습니다. 알츠하이머병, 파킨슨병 등 신경퇴행성 질환에서 확고한 포트폴리오를 보유하고 있어 우위를 점하고 있습니다. 각 사들은 신경염증이나 신경재생과 같은 새로운 기전을 타겟으로 하는 혁신적인 신약개발에 집중하고 있습니다. 또한, 유전자 치료나 줄기세포 연구와 같은 첨단 기술을 활용하기 위해 대형 제약사와 중소 바이오텍 기업과의 공동연구도 활발히 진행되고 있습니다.

신경퇴행성 질환의 유병률 증가와 치료법 개선의 필요성이 시장 점유율을 둘러싼 치열한 경쟁을 부추기고 있습니다. 규제 당국의 승인 과정과 연구개발비용의 급증으로 인해 복잡성이 증가하고, 막대한 자원과 전문성을 갖춘 소수의 지배적인 기업이 존재하게 될 것입니다. 신규 시장 진출기업들은 차별화를 위해 틈새 시장과 획기적인 치료법을 끊임없이 모색하고 있습니다.

목차

제1장 신경 보호 시장 개요

  • 조사 범위
  • 시장 추정 기간

제2장 주요 요약

  • 시장 내역
  • 경쟁 인사이트

제3장 신경 보호 주요 시장 동향

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 시장 향후 동향

제4장 신경 보호 시장 : 산업 분석

  • PEST 분석
  • Porter의 Five Forces 분석
  • 시장 성장 전망 : 맵핑
  • 규제 체제 분석

제5장 신경 보호 시장 : 높아지는 지정학적 긴장의 영향

  • COVID-19 팬데믹의 영향
  • 러시아-우크라이나 전쟁의 영향
  • 중동 분쟁의 영향

제6장 신경 보호 시장 구도

  • 신경 보호 시장 점유율 분석(2024년)
  • 주요 제조업체별 분석 데이터
    • 기존 기업 분석
    • 신규 기업 분석

제7장 신경 보호 시장 : 제품 유형별

  • 개요
    • 부문별 점유율 분석 : 제품 유형별
    • 약제
      • 항산화물질
      • 항염증제
      • 칼슘 채널 차단제
      • 자유 라디칼 제거제(Free radical scavengers)
    • 장비

제8장 신경 보호 시장 : 적응증별

  • 개요
    • 부문별 점유율 분석 : 적응증별
    • 파킨슨병
    • 알츠하이머병
    • 뇌졸중
    • 다발성 경화증
    • 루게릭병(ALS)
    • 외상성 뇌손상(TBI)
    • 기타

제9장 신경 보호 시장 : 작용기전별

  • 개요
    • 부문별 점유율 분석 : 작용기전별
    • 항산화물질
    • 미토콘드리아 보호
    • 염증 조절
    • 칼슘 조절
    • 신경 신생 자극
    • 유전자 치료 기반

제10장 신경 보호 시장 : 최종사용자별

  • 개요
    • 부문별 점유율 분석 : 최종사용자별
    • 병원
    • 진료소
    • 연구기관
    • 재택치료

제11장 신경 보호 시장 : 지역별

  • 서론
  • 북미
    • 개요
    • 북미의 주요 제조업체
    • 미국
    • 캐나다
  • 유럽
    • 개요
    • 유럽의 주요 제조업체
    • 독일
    • 영국
    • 프랑스
    • 이탈리아
    • 스페인
    • 네덜란드
    • 스웨덴
    • 러시아
    • 폴란드
    • 기타
  • 아시아태평양(APAC)
    • 개요
    • 아시아태평양의 주요 제조업체
    • 중국
    • 인도
    • 일본
    • 한국
    • 호주
    • 인도네시아
    • 태국
    • 필리핀
    • 기타
  • 라틴아메리카(LATAM)
    • 개요
    • 라틴아메리카의 주요 제조업체
    • 브라질
    • 멕시코
    • 아르헨티나
    • 콜롬비아
    • 기타
  • 중동 및 아프리카(MEA)
    • 개요
    • 중동 및 아프리카의 주요 제조업체
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 이스라엘
    • 튀르키예
    • 알제리
    • 이집트
    • 기타

제12장 주요 벤더 분석 : 신경 보호 업계

  • 경쟁 대시보드
    • 경쟁 벤치마킹
    • 경쟁 포지셔닝
  • 기업 개요
    • Biogen Inc.
    • Eli Lilly and Co.
    • Novartis AG
    • Roche Holding AG
    • Merck &Co.
    • Pfizer Inc.
    • Amgen Inc.
    • AbbVie Inc.
    • Johnson &Johnson
    • Sanofi SA
    • Teva Pharmaceutical Industries Ltd.
    • Takeda Pharmaceutical Company Limited
    • Lundbeck A/S
    • GlaxoSmithKline(GSK)
    • AstraZeneca plc
    • Eisai Co., Ltd.
    • Neurocrine Biosciences, Inc.
    • Axovant Gene Therapies

제13장 AnalystView의 전방위적 분석

LSH 25.05.07

REPORT HIGHLIGHT

Neuroprotection Market size was valued at US$ 34,092.43 Million in 2024, expanding at a CAGR of 7.42% from 2025 to 2032.

The neuroprotection market refers to the industry focused on developing therapies and products aimed at protecting the nervous system, particularly the brain and spinal cord, from damage caused by diseases, injuries, or aging. This market addresses conditions such as Alzheimer's disease, Parkinson's disease, stroke, multiple sclerosis, and traumatic brain injuries. Neuroprotective treatments can involve drug therapies, antioxidants, neurotrophic factors, and other interventions that help prevent or reduce neuronal damage.

The growth of this market is driven by the increasing prevalence of neurological disorders, advances in medical research, and the rising demand for effective treatments. Additionally, the aging global population further fuels the market as neurodegenerative diseases become more common. Companies are heavily investing in innovative solutions, leading to an expanding range of therapeutic options in neuroprotection.

Neuroprotection Market- Market Dynamics

Advancements in biomarker discovery for early-stage neurodegenerative disease diagnosis.

Advancements in biomarker discovery play a critical role in the early diagnosis of neurodegenerative diseases, significantly driving the neuroprotection market. Biomarkers help detect neurological disorders at their onset, enabling earlier and more effective intervention, which is crucial for improving patient outcomes. These discoveries facilitate personalized treatment approaches, as biomarkers can identify specific disease subtypes and predict progression. Enhanced diagnostic precision can reduce healthcare costs by ensuring timely therapies and better management.

Academic institutions and research organizations are leading the charge, with collaborations fostering breakthroughs. For instance, the National Institute on Aging (NIA) in the U.S. is actively funding biomarker research for Alzheimer's disease, which has led to the development of several promising diagnostic markers. According to the NIA, over $300 million is allocated annually toward Alzheimer's research, much of which focuses on biomarker advancements. These developments not only enhance diagnostic accuracy but also support the broader trend of precision medicine in neurodegenerative care.

Neuroprotection Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.42% over the forecast period (2025-2032)

Based on product type segmentation, Medications was predicted to show maximum market share in the year 2024

Based on Disease Indication segmentation, Alzheimer's disease was the leading Disease Indication in 2024

Based on Mechanism of Action segmentation, Antioxidants was the leading Mechanism of Action in 2024

Based on End-User segmentation, Hospitals was the leading End-User in 2024

On the basis of region, North America was the leading revenue generator in 2024

Neuroprotection Market- Segmentation Analysis:

The Global Neuroprotection Market is segmented on the basis of Product Type, Disease Indication, Mechanism of Action, End User, and Region.

The market is divided into two categories based on product type: Medication and Devices. In the neuroprotection market, medications are the most significant segment. They dominate the market due to their direct role in treating neurological diseases and conditions like Alzheimer's, Parkinson's, and multiple sclerosis. Medications, including neuroprotective drugs, are designed to slow disease progression, protect neurons from damage, and improve patients' quality of life. This segment benefits from ongoing research, clinical trials, and regulatory approvals, driving demand for novel pharmaceutical treatments. The market for neuroprotective medications is expected to continue growing as advancements in neuroscience lead to more effective therapies.

The market is divided into six categories based on Disease Indication: Parkinson's Disease, Alzheimer's Disease, Stroke, Multiple Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Traumatic Brain Injury (TBI), Others. In the neuroprotection market, Alzheimer's disease is the most significant disease indication. It holds the largest share due to the high prevalence of the disease worldwide and the increasing aging population. Alzheimer's triggers widespread neurodegeneration, creating a substantial demand for neuroprotective therapies aimed at slowing its progression. Ongoing advancements in drug development and the increasing focus on finding effective treatments have propelled this segment forward. As the need for innovative treatments grows, Alzheimer's disease remains a focal point for researchers and pharmaceutical companies.

Neuroprotection Market- Geographical Insights

The North American neuroprotection market is experiencing significant growth, driven by an aging population, increasing prevalence of neurodegenerative diseases like Alzheimer's, Parkinson's, and multiple sclerosis, and advances in biotechnology and pharmaceuticals. The U.S. holds the largest share, owing to strong healthcare infrastructure, substantial research funding, and a high demand for therapeutic solutions. Canada is also contributing to the market with growing investments in neuroprotective research and development. Furthermore, there is a rising focus on early-stage interventions and preventative treatments, as well as emerging drug therapies. Government initiatives and collaborations between academic institutions and private sectors are enhancing innovation in neuroprotective agents. However, challenges such as high drug development costs and regulatory hurdles remain. Despite this, the market outlook remains optimistic, with key players in the industry exploring novel treatment strategies to address unmet medical needs.

The United States is the dominant country in the North American neuroprotection market, largely due to its advanced healthcare system, high level of research and development, and substantial government funding for medical innovation. The country is home to many leading biotech and pharmaceutical companies focused on neurodegenerative diseases, contributing to the rapid development and commercialization of neuroprotective therapies. Additionally, the large and aging population in the U.S. presents a growing demand for treatments, making it a key driver of market growth.

Neuroprotection Market- Competitive Landscape:

The competitive landscape of the neuroprotection market is characterized by intense rivalry among pharmaceutical companies, biotech firms, and research institutions, all vying to develop effective treatments for neurological disorders. Major players such as Biogen, Novartis, and Eli Lilly dominate with established portfolios in neurodegenerative diseases like Alzheimer's and Parkinson's. Companies are focusing on innovative drug discovery, targeting new mechanisms like neuroinflammation and neuroregeneration. The market also sees collaborations between large pharmaceutical firms and smaller biotech companies to leverage advanced technologies like gene therapy and stem cell research.

The increasing prevalence of neurodegenerative diseases and the need for improved treatments drive fierce competition for market share. Regulatory approval processes and the high cost of R&D add layers of complexity, leading to a few dominant players with significant resources and expertise. New entrants are constantly looking for niche areas and breakthrough therapies to differentiate themselves.

Recent Developments:

In November 2023, the US Food and Drug Administration (FDA) met with BrainStorm Cell Therapeutics to discuss NurOwn, a device with the potential to alleviate symptoms of ALS. The meeting discussed the overall protocol design of a potential confirmatory Phase III trial.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NEUROPROTECTION MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Biogen Inc.
  • Eli Lilly and Co.
  • Novartis AG
  • Roche Holding AG
  • Merck & Co.
  • Pfizer Inc.
  • Amgen Inc.
  • AbbVie Inc.
  • Johnson & Johnson
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Lundbeck A/S
  • GlaxoSmithKline (GSK)
  • AstraZeneca plc
  • Eisai Co., Ltd.
  • Neurocrine Biosciences, Inc.
  • Axovant Gene Therapies

GLOBALNEUROPROTECTION MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Medication
  • Antioxidants
  • Anti-inflammatory drugs
  • Calcium channel blockers
  • Free radical scavengers
  • Devices

GLOBAL NEUROPROTECTION MARKET, BY DISEASE INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Parkinson's Disease
  • Alzheimer's Disease
  • Stroke
  • Multiple Sclerosis
  • Amyotrophic Lateral Sclerosis (ALS)
  • Traumatic Brain Injury (TBI)
  • Others

GLOBAL NEUROPROTECTION MARKET, BY MECHANISM OF ACTION- MARKET ANALYSIS, 2019 - 2032

  • Antioxidants
  • Mitochondrial Protection
  • Inflammation Modulation
  • Calcium Regulation
  • Neurogenesis Stimulation
  • Gene Therapy-Based

GLOBAL NEUROPROTECTION MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Clinics
  • Research Institutes
  • Home Care Settings

GLOBAL NEUROPROTECTION MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Neuroprotection Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Neuroprotection Market Snippet by Product Type
    • 2.1.2. Neuroprotection Market Snippet by Disease Indication
    • 2.1.3. Neuroprotection Market Snippet by Mechanism of Action
    • 2.1.4. Neuroprotection Market Snippet by End User
    • 2.1.5. Neuroprotection Market Snippet by Country
    • 2.1.6. Neuroprotection Market Snippet by Region
  • 2.2. Competitive Insights

3. Neuroprotection Key Market Trends

  • 3.1. Neuroprotection Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Neuroprotection Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Neuroprotection Market Opportunities
  • 3.4. Neuroprotection Market Future Trends

4. Neuroprotection Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Neuroprotection Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Neuroprotection Market Landscape

  • 6.1. Neuroprotection Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Neuroprotection Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2024 & 2032 (%)
    • 7.1.2. Medication
      • 7.1.2.1. Antioxidants
      • 7.1.2.2. Anti-inflammatory drugs
      • 7.1.2.3. Calcium channel blockers
      • 7.1.2.4. Free radical scavengers
    • 7.1.3. Devices

8. Neuroprotection Market - By Disease Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Disease Indication, 2024 & 2032 (%)
    • 8.1.2. Parkinson's Disease
    • 8.1.3. Alzheimer's Disease
    • 8.1.4. Stroke
    • 8.1.5. Multiple Sclerosis
    • 8.1.6. Amyotrophic Lateral Sclerosis (ALS)
    • 8.1.7. Traumatic Brain Injury (TBI)
    • 8.1.8. Others

9. Neuroprotection Market - By Mechanism of Action

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Mechanism of Action, 2024 & 2032 (%)
    • 9.1.2. Antioxidants
    • 9.1.3. Mitochondrial Protection
    • 9.1.4. Inflammation Modulation
    • 9.1.5. Calcium Regulation
    • 9.1.6. Neurogenesis Stimulation
    • 9.1.7. Gene Therapy-Based

10. Neuroprotection Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Clinics
    • 10.1.4. Research Institutes
    • 10.1.5. Home Care Settings

11. Neuroprotection Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Neuroprotection Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Neuroprotection Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Neuroprotection Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Neuroprotection Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Neuroprotection Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Neuroprotection Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Biogen Inc.
    • 12.2.2. Eli Lilly and Co.
    • 12.2.3. Novartis AG
    • 12.2.4. Roche Holding AG
    • 12.2.5. Merck & Co.
    • 12.2.6. Pfizer Inc.
    • 12.2.7. Amgen Inc.
    • 12.2.8. AbbVie Inc.
    • 12.2.9. Johnson & Johnson
    • 12.2.10. Sanofi S.A.
    • 12.2.11. Teva Pharmaceutical Industries Ltd.
    • 12.2.12. Takeda Pharmaceutical Company Limited
    • 12.2.13. Lundbeck A/S
    • 12.2.14. GlaxoSmithKline (GSK)
    • 12.2.15. AstraZeneca plc
    • 12.2.16. Eisai Co., Ltd.
    • 12.2.17. Neurocrine Biosciences, Inc.
    • 12.2.18. Axovant Gene Therapies

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제